Paul K. Audhya, the Chief Medical Officer at KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), executed a disposition of shares in the company's common stock on May 22, 2026. Specifically, Mr. Audhya sold 2,685 shares, amounting to $71,916, with each share trading at $26.7844.
This sale took place when the company's stock was trading in proximity to its 52-week high of $26.85. The context for this recent activity is notable given that KalVista Pharmaceuticals had achieved a substantial return of 134% over the past year.
Details of the Stock Transaction
According to a footnote within the filing documentation, the disposition was executed solely to satisfy tax withholding obligations. These obligations stemmed from the vesting and settlement of restricted stock units (RSUs), meaning the transaction did not constitute a voluntary or discretionary sale by Mr. Audhya.
Recent Compensation Activity
The activity preceding the May 22 sale provides further context regarding Mr. Audhya's compensation structure. On May 21, 2026, he acquired an additional 6,250 shares of common stock following the settlement of restricted stock units. It is important to note that each RSU represents a contingent right granting one share of the company’s common stock upon settlement and requires no consideration.
These RSUs were structured to vest in increments across quarterly periods. The vesting schedule dictated that 1/16th of the total award would become available on each quarterly anniversary starting from May 21, 2025, contingent upon his continued service with the company.
Current Holdings and Valuation Context
Following these recent transactions, Mr. Audhya's direct holdings in KalVista Pharmaceuticals common stock total 147,499 shares. In addition to this, he maintains an ownership stake of 68,750 restricted stock units.
Regarding the company’s valuation, analysis provided by InvestingPro suggests that the stock currently appears fairly valued. Detailed insights and comprehensive research reports are available through the platform, covering KALV and over 1,400 other US equities.
The Pending Merger Agreement
A major development influencing the stock's environment is KalVista Pharmaceuticals’ merger agreement to be acquired by Chiesi Group. Under this deal, shareholders would receive $27.00 per share in cash, an offer that values the company at approximately $1.9 billion.
This proposed acquisition price represents a 36% premium when compared to KalVista’s 30-day volume-weighted average share price. The board of directors for both Kalvista and Chiesi have unanimously approved this transaction. The closing of the deal is anticipated in the third quarter of 2026, subject to customary closing conditions.
Analyst Reactions Following Announcement
The merger announcement prompted immediate adjustments from financial analysts. H.C. Wainwright downgraded Kalvista Pharmaceuticals stock, moving its rating to Neutral from Buy. The firm adjusted its price target accordingly, lowering it to $27 from the previous level of $37.
Similarly, Jones Trading also revised its rating for the stock, downgrading it to Hold from Buy, and setting a new price target at $27, which was reduced from an earlier target of $39. These analyst adjustments align directly with the acquisition price offered by Chiesi Group, underscoring the significance of the proposed transaction.
Overall, the merger announcement has generated considerable attention among both investors and analysts, highlighting a substantial premium over recent trading levels for Kalvista Pharmaceuticals.